Skip to content
Review

Efficacy and safety of biologic therapies for chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis

2026 · International Journal of Medicine in Developing Countries · pp. 1 · 0 citations

TL;DR

Biologic therapies targeting IgE, IL-5/IL-5Rα, and TSLP produce clinically meaningful, statistically significant improvements in nasal polyp size and sinonasal quality of life compared with placebo in patients with CRSwNP, although the magnitude of effect varies substantially by mechanism and population.

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous, type 2-inflammation-driven disease of the sinonasal mucosa that is frequently refractory to intranasal and systemic corticosteroids and often recurs after endoscopic sinus surgery. Biologic agents targeting distinct upstream and downstream type 2 inflammatory mediators have been evaluated in phase 3 randomized controlled trials (RCTs) as add-on therapy to standard of care. This study aimed to systematically review and meta-analyze randomized, placebo-controlled trials of biologic therapies for CRSwNP, and to quantify their effect on nasal polyp size, sinonasal symptom burden, and the need for surgery or systemic corticosteroids. Databases were searched from inception to 15 August 2026, together with ClinicalTrials.gov and the WHO ICTRP. Five trial comparisons from four publications (62â€"413 randomized patients per trial) had verified extractable data and were pooled quantitatively. All five reported statistically significant improvement in total NPS versus placebo at their respective primary endpoints (24â€"52 weeks); the pooled random-effects mean/median difference was âˆ'1.02 points (95% CI âˆ'1.64 to âˆ'0.41; I² ≤ 92.8%). SNOT-22 total score also improved across trials (pooled difference âˆ'16.10 points, 95% CI âˆ'23.57 to âˆ'8.62; I² ≤ 87.4%), although the effect in OSTRO (benralizumab) did not reach statistical significance. Biologic therapies targeting IgE, IL-5/IL-5Rα, and TSLP produce clinically meaningful, statistically significant improvements in nasal polyp size and sinonasal quality of life compared with placebo in patients with CRSwNP, although the magnitude of effect varies substantially by mechanism and population, and cross-trial pooling should be interpreted cautiously given the very high statistical heterogeneity.

View source

Similar papers

Oct 2026

Efficacy of Dupilumab for Patients with Chronic Rhinosinusitis without Nasal Polyps: a Randomized Double-Blind Placebo Controlled Phase II Study.

The observed trend toward enhanced benefit in T2-high patients supports the potential for endotype-directed therapy and underscores the need for larger studies to evaluate the role of T2-targeted biologics in CRSsNP management.

J. Tversky, Andrew P. Lane, John T. Schroeder et al. · 0 citations
Open access Oct 2026

Efficacy and safety of tezepelumab in Japanese patients with chronic rhinosinusitis with nasal polyps: A subpopulation analysis of the randomized WAYPOINT study.

OBJECTIVE Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, effectively reduced polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab also reduced the need for nasal polyp surgery and systemic corticosteroids (SCS) in the phase 3 WAYPOINT study across 10 countri...

N. Otori, Daiju Sakurai, Genki Iwai et al. · 0 citations
Review Open access Oct 2026

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps: A Critical Evidence-Based Review

Objectives: Nasal polyps are present in a substantial proportion of patients with chronic rhinosinusitis (CRSwNP) and are driven, in most Western populations, by type 2 inflammation. Conventional treatment with corticosteroids and endoscopic sinus surgery frequently fails to provide durable disease control, particularl...

A. Osamah, Abdul-Razzaq Al-Itbi, Mohammed Hasan et al. · 0 citations
Review Open access Sep 2026

Predictive biomarkers of biologic therapy response in chronic rhinosinusitis with nasal polyps: a systematic review

Background Biologic therapies have transformed management of severe chronic rhinosinusitis with nasal polyps (CRSwNP), but response variability persists. Baseline biomarkers may identify patients most likely to benefit, yet no marker is validated for routine clinical use. This systematic review evaluated baseline bioma...

Omair Al Hussain · 0 citations
Review Open access Oct 2026

Topical Nasal Furosemide for the Prevention of Postoperative Nasal Polyp Recurrence: A Systematic Review

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is defined by high postoperative recurrence rates. While standard therapies target inflammation, the crucial role of mucosal edema secondary to epithelial ion transport dysregulation offers a new therapeutic target. This systematic review aims to criticall...

Felipe Schulz · 0 citations
Review Open access Sep 2026

New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic airway disease characterized mainly by type 2 inflammation, which seriously impairs patients' quality of life and imposes a huge economic burden. Traditional treatments cannot eradicate underlying immune disorders, leading to high postoperative r...

B. Huang, Yue Xu, Ye Tian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.